Silihan lan utang jangka dawa perusahaan: eyenovia.com (EYEN)

The market price confirmed by the chart indicates the development of Eyenovia, Inc. (EYEN), which is implementing Optejet technology to combat myopia and presbyopia, preparing an FDA application for MicroPine by 2026. The current metric stands at 0.00. The business relies on stable demand in ophthalmology; therefore, its success is determined solely by the efficacy of the therapy rather than economic fluctuations.

This indicator aggregates obligations with maturities exceeding one year, reflecting the long-term capital structure of Eyenovia, Inc. (EYEN). The metric determines the level of financial leverage and the business's reliance on external borrowings. The stability of this figure is critical for financing the commercialization of the Optejet system and clinical trials for new drugs. By analyzing the time series of the company's long-term debt, an investor can assess the balance between solvency and the pace of expansion within the ophthalmology sector.